Scholars@Duke
Georgia Marie Beasley

Georgia Marie Beasley

Associate Professor of Surgery
Surgical Oncology
georgia.beasley@duke.edu
Erwin Rd, Durham, NC 27710
Dept of Surgery, Durham, NC 27710

Scholarly Works - Conferences

A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.

Conference Journal of Clinical Oncology · June 1, 2026 9518Background: Advanced melanoma has a high mortality rate; however, survival for pa ... Full text Cite

Abstract 4146: Melanocytic transcriptional state is an independent marker of survival in metastatic melanoma

Conference Cancer Research · April 3, 2026 AbstractIntroduction:Advanced cutaneous melanoma shows substantial heterogeneity in clinical outcomes, even among patients clas ... Full text Cite

Response analysis for injected and non-injected lesions and of the safety and efficacy of superficial and deep/visceral RP1 injection in the registrational cohort of anti–PD-1–failed melanoma patients of the IGNYTE trial.

Conference Journal of Clinical Oncology · June 2025 9537Background: The IGNYTE trial (NCT03767348) primary analysis of RP1 (vusolimogene oderparepvec) plusnivolumab (nivo) showe ... Full text Cite

Biosafety analysis from the skin cancer cohorts in the IGNYTE clinical trial of RP1.

Conference Journal of Clinical Oncology · June 2025 9534Background: RP1 (vusolimogene oderparepvec) is an HSV–based oncolytic immunotherapy administered intratumorally. RP1 + ni ... Full text Cite

Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT).

Conference Journal of Clinical Oncology · June 2025 TPS9608Background: When melanoma metastases are detected clinically in regional lymph nodes (cLNs) without distant metastasis ... Full text Cite

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.

Conference Journal of Clinical Oncology · June 1, 2025 e21519Background: Uveal melanoma has a poor prognosis once liver metastases occur. Melphalan/Hepatic Delivery System (Melphalan/HDS) is a drug/device combination therapy used for liver-directed treatment of metastatic UM (mUM) patients. The purpose of the ... Full text Cite

Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma.

Conference Journal of Clinical Oncology · June 2025 9571Background: Circulating tumor DNA (ctDNA) has emerged as an important biomarker for early recurrence detection and monito ... Full text Cite

Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort.

Conference Ann Surg Oncol · March 2025 BACKGROUND: Nodal surveillance (NS) has overtaken completion lymphadenectomy as the preferred management for sentinel node-positive (SLN+) melanoma, but requires frequent exams and nodal ultrasound (US). Social determinants of health (SDoH) may affect US a ... Full text Link to item Cite

Whole Transcriptome Profiling of Patients with In Transit Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · March 2024 Link to item Cite

Melanin imaging with pump-probe microscopy for diagnosis of metastatic melanoma

Conference 2024 Conference on Lasers and Electro-Optics, CLEO 2024 · January 1, 2024 Melanoma, the most aggressive skin cancer, is responsible for around 10,000 deaths annually.Wearedevelopingadiagnosticbiomarkerbasedonfemtosecondpump-probemicroscopy of melanin, a natural pigment found in most melanoma. ... Cite

Melanin imaging with pump-probe microscopy for diagnosis of metastatic melanoma

Conference 2024 Conference on Lasers and Electro Optics CLEO 2024 · January 1, 2024 Melanoma, the most aggressive skin cancer, is responsible for around 10,000 deaths annually.Wearedevelopingadiagnosticbiomarkerbasedonfemtosecondpump-probemicroscopy of melanin, a natural pigment found in most melanoma. ... Full text Cite

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.

Conference Journal of Clinical Oncology · June 1, 2023 9509 Background: Patients (pts) with melanoma who progress on anti–PD-1 therapy (anti–PD-1–failed) have limited treatment options. RP1 is an HSV-1–based oncolytic immunotherapy expressing human GM-CSF and a fusogenic protein (GAL ... Full text Cite

Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.

Conference Journal of Clinical Oncology · June 1, 2023 2588 Background: Immunotherapies, including immune checkpoint inhibitors (ICI), have revolutionized the treatment of many cancers, producing significant improvements in survival in patients with many different cancers. However, t ... Full text Cite

A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · June 1, 2023 2569 Background: MEM-288 is a conditionally-replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust dendritic cell-mediated s ... Full text Cite

Abstract CT053: Merlin_001: a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients

Conference Cancer Research · April 14, 2023 AbstractBackground: Sentinel lymph node biopsy (SLNB) provides important staging and prognostic information that guides surveillance and adjuvant systemic therapy decisions for patients with cutaneous mel ... Full text Cite

Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity

Conference Cancer Research · April 14, 2023 AbstractBackground: MEM-288 is a conditionally-replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust ... Full text Cite

Improved survival of multiple vs single primary melanomas

Conference JOURNAL OF INVESTIGATIVE DERMATOLOGY · August 2022 Link to item Cite

In-transit Melanoma: A Multi-institutional Analysis of Outcomes

Conference ANNALS OF SURGICAL ONCOLOGY · May 2022 Link to item Cite

Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.

Conference Journal of Clinical Oncology · May 20, 2021 9576 Background: While management of the nodal basin for melanoma has largely moved to observation for microscopic sentinel lymph node (SLN) metastasis, complete lymph node dissection (CLND) remains the current standard of care f ... Full text Cite

Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.

Conference Journal of Clinical Oncology · May 20, 2021 9510 Background: Ocular melanoma, the most common intraocular malignancy, frequently metastasizes to the liver but to date there is no established standard of care for hepatic-dominant ocular melanoma patients. The FOCUS trial be ... Full text Cite

The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma.

Conference Ann Surg Oncol · December 2020 PURPOSE: We hypothesized that initial biopsy may understage acral lentiginous melanoma (ALM) and lead to undertreatment or incomplete staging. Understanding this possibility can potentially aid surgical planning and improve primary tumor staging. METHODS: ... Full text Link to item Cite

Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.

Conference Eur J Surg Oncol · November 2020 INTRODUCTION: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study was to identify predict ... Full text Link to item Cite

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.

Conference Ann Surg Oncol · December 2019 BACKGROUND: Talimogene laherparepvec (T-VEC) is the first injectable oncolytic viral therapy approved for in-transit melanoma metastasis, with a reported overall response rate (ORR) of 25% and complete response rate (CRR) of 10%. To ascertain the role of p ... Full text Link to item Cite

Mind the Gap: Gendered Publication Trends in Academic Oncology

Conference International Journal of Radiation Oncology*Biology*Physics · September 2019 Full text Cite

Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis.

Conference Ann Surg Oncol · August 2019 BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose regional chemotherapy to patients with locally advanced or in-transit melanoma located on a limb. The current international multicenter study evaluated the ... Full text Link to item Cite

Overall Survival Improved for Contemporary Patients with Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2019 Link to item Cite

Substage-Specific Survival in Acral Lentiginous Melanoma

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2019 Link to item Cite

Hepatic arterial melphalan perfusion of liver predominant uveal melanoma metastasis

Conference INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · June 1, 2017 Link to item Cite